Importance The incidence of acute lymphoblastic leukemia (ALL) and lymphoblastic
lymphoma (LBL) in adolescent and young adult (AYA) patients (age range, 15-39 years) in …

Acute lymphoblastic leukemia (ALL) is a malignancy of lymphoid progenitor cells occurring
at an annual incidence rate of approximately 1.1–2.1 per 100,000 person-years globally …

L-asparaginase, which hydrolyzes asparagine into aspartic acid and ammonia, is frequently
used to treat acute lymphoblastic leukaemia in children. When combined with other …

Drug-related toxicities represent an important clinical concern in chemotherapy, genetic
variants could help tailoring treatment to patient. A pharmacogenetic multicentric study was …

Introduction AYA-ALL differs from pediatric ALL in terms of clinical, biological, psychosocial
factors and access to care and has an inferior outcome. It is now being recognized that …

The “Veneto Cancer Registry” records melanoma as the most common cancer diagnosed in
males and the third common cancer in females under 50 years of age in the Veneto Region …

Adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) have
significantly worse outcomes than their younger counterparts. Current treatment guidelines …

The outcomes of adult B‐cell acute lymphoblastic leukemia (ALL) remain poor. Recent
advancements in the field of leukemia research show potential for improved patient care …

Systemic therapy of melanoma has made tremendous progress recently for advanced stage
patients in terms of excellent, temporary responses through targeting underlying biology of …

The survival rate for children with acute lymphoblastic leukemia (ALL) has dramatically
improved over the last 50 years. However, for those in the adolescent and young adult (AYA) …